Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular EDEMA

Retina

Volumn 34, Issue 4, 2014, Pages 741-748

  Sonoda, Shozo ^a   Sakamoto, Taiji ^a   Yamashita, Takehiro ^a   Shirasawa, Makoto ^a   Otsuka, Hiroki ^a   Sonoda, Yasushi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; VASCULOTROPIN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; EYE SWELLING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PREOPERATIVE EVALUATION; RETINA DETACHMENT; RETROSPECTIVE STUDY; VITRECTOMY; VITREOUS BODY;

ADULT; AGED; CYTOKINES; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84897571791     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182a48917     Document Type: Article

References (39)

1. Arun CS, Al-Bermani A, Stannard K, Taylor R. Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age population. Diabet Med 2009;26:489-492.
2. Nordwall M, Bojestig M, Arnqvist HJ, et al; Diabetes Complications Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linköping Diabetes Complications Study. Diabetologia 2004;47:1266-1272.
3. Sloan FA, Belsky D, Ruiz D Jr, Lee P. Changes in incidence of diabetes mellitus-related eye disease among US elderly persons, 1994-2005. Arch Ophthalmol 2008;126:1548-1553.
4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227-1239.
5. Marmor MF. Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 1999;97:239-249.
6. Whitmire W, Al-Gayyar MM, Abdelsaid M, et al. Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far. Mol Vis 2011;17:300-308.
7. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999;127:688-693.
8. Gaucher D, Sebah C, Erginay A, et al. Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema. Am J Ophthalmol 2008;145:289-296.
9. Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005;140:200-206.
10. Kim BY, Smith SD, Kaiser PK Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol 2006;142:405-412.
11. Kim M, Lee P, Kim Y, et al. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica 2011;226:138-144.
12. Ota M, Nishijima K, Sakamoto A, et al. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology 2010;117:1996-2002.
13. Wu PC, Lai CH, Chen CL, Kuo CN. Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Ther 2012;28:59-64.
14. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N EnglJ Med 1994;331:1480-1487.
15. Arimura N, Otsuka H, Yamakiri K, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009;116:921-926.
16. Funatsu H, Noma H, Mimura T, Eguchi S. Vitreous inflammatory factors and macular oedema. Br J Ophthalmol 2012;96:302-304.
17. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009;116:2158-2164.
18. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213.
19. O'Reilly S, Ciechomska M, Cant R, et al. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012;23: 99-107.
20. Tosa M, Ghazizadeh M, Shimizu H, et al. Global gene expression analysis of keloid fibroblasts in response to electron beam irradiation reveals the involvement of interleukin-6 pathway. J Invest Dermatol 2005;124:704-713.
21. Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 2010;51:2388-2392.
22. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Oph-thalmol 2011;152:686-694.
23. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report No. 1. Arch Ophthalmol 1985;103:1796-1806.
24. Otsuka H, Arimura N, Sonoda S, et al. Stromal cell-derived factor-1 is essential for photoreceptor cell protection in retinal detachment. Am J Pathol 2010;177:2268-2277.
25. Menke MN, Dabov S, Knecht P, Sturm V. Reproducibility of retinal thickness measurements in healthy subjects using spec-tralis optical coherence tomography. Am J Ophthalmol 2009; 147:467-472.
26. Terasaki H, Shirasawa M, Yamashita T, et al. Comparison of foveal microstructure imaging with different spectral domain optical coherence tomography machines. Ophthalmology 2012;119:2319-2327.
27. Sonoda Y, Arimura N, Shimura M, Sakamoto T. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion. Retina 2011;31:290-297.
28. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-79.
29. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.
30. Das A, McGuire PG. Retinal and choroidal angiogenesis: path-ophysiology and strategies for inhibition. Prog Retin Eye Res 2003;22:721-748.
31. Elman MJ, Bressler NM, Qin H, et al; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-614.
32. Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology 2012;119:2179-2188.
33. Aloisi F. Immune function of microglia. Glia 2001;36:165-179.
34. Soliman W, Sander B, Hasler PW, Larsen M. Correlation between intraretinal changes in diabetic macular oedema seen in fluorescein angiography and optical coherence tomography. Acta Ophthalmol 2008;86:34-39.
35. Yeung L, Lima VC, Garcia P, et al. Correlation between spectral domain optical coherence tomography findings and fluorescein angiography patterns in diabetic macular edema. Ophthalmology 2009;116:1158-1167.
36. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 1996;122: 258-260.
37. Kumagai K, Furukawa M, Ogino N, et al. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009;29:464-472.
38. Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevaci-zumab. Retina 2010;30:1412-1419.
39. Miller JW. Treatment of age-related macular degeneration: beyond VEGF. Jpn J Ophthalmol 2010;54:523-528.